DYAX 13.50 Dyax Corp $DYAX Hit a 52 week high of 13.66

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 11:29 AM

DYAX 13.50 Dyax Corp $DYAX Hit a 52 week high of 13.66 Closing the day 09:44 at 13.50 +0.03 +0.22% With a day low of 13.43 and a total volume of 52,446.

DYAX Recent Posts: http://investorshangout.com/Dyax-Corp-DYAX-53955/

DYAX Dyax Corp Recent Headline News

Dyax Up 73.8% Since SmarTrend Uptrend Call (DYAX)
Comtex SmarTrend(R) - Mon Nov 10, 4:46PM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 6 months, Dyax has returned 73.76% as of today's recent price of $13.18.
DYAX: 13.35 (-0.12)

Why Dyax (DYAX) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:42AM CST
Dyax's stock not only has a decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well, suggesting that it could be a solid choice for investors.
DYAX: 13.35 (-0.12)

Can Dyax (DYAX) Stock Continue to Grow Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 7:49AM CST
Dyax possess a positive long term growth rate and favorable Zacks Rank
DYAX: 13.35 (-0.12)

Dyax Shares Up 62.1% Since SmarTrend's Buy Recommendation (DYAX)
Comtex SmarTrend(R) - Mon Nov 03, 10:56AM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 62.07% as of today's recent price of $12.29.
DYAX: 13.35 (-0.12)

Dyax Corp. Announces Expansion of Phase 1b Clinical Trial for DX-2930
Business Wire - Mon Nov 03, 6:30AM CST
Dyax Corp. (NASDAQ: DYAX) today announced the expansion of its ongoing Phase 1b clinical trial evaluating DX-2930 to include additional patients and dosing cohorts. Dyax is developing DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein, as a subcutaneous injection for prevention of hereditary angioedema (HAE) attacks.
DYAX: 13.35 (-0.12)

BIND Therapeutics, Inc. (BIND) Surges: Stock Rises 14.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:11AM CDT
BIND Therapeutics, Inc. (BIND) was a big mover last session, as the company saw its shares rise over 14% on the day.
BIIB: 319.06 (-1.96), AMAG: 34.76 (-0.17), BIND: 10.05 (+0.07), DYAX: 13.35 (-0.12)

Update: Biotech Dyax Exceeds Q3 Estimates With The Future Looking Bright
David Zanoni - at Seeking Alpha - Thu Oct 30, 11:15AM CDT

DYAX: 13.35 (-0.12)

Will Dyax (DYAX) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:04AM CDT
Will Dyax (DYAX) Continue to Surge Higher?
DYAX: 13.35 (-0.12)

Dyax ups earnings 87% in Q3
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 8:53AM CDT

DYAX: 13.35 (-0.12)

Dyax's (DYAX) CEO Gustav Christiansen on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Oct 28, 7:54PM CDT

DYAX: 13.35 (-0.12)

Dyax beats Street 3Q forecasts
Automated Insights - Tue Oct 28, 4:48PM CDT
BURLINGTON, Mass. (AP) _ Dyax Corp. (DYAX) on Tuesday reported a loss of $816,000 in its third quarter.
DYAX: 13.35 (-0.12)

Dyax (DYAX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Oct 28, 3:55PM CDT

DYAX: 13.35 (-0.12)

Dyax beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:16PM CDT

DYAX: 13.35 (-0.12)

Dyax Corp. Announces Third Quarter 2014 Financial Results
Business Wire - Tue Oct 28, 3:01PM CDT
Dyax Corp. (NASDAQ: DYAX) today announced financial results for the third quarter ended September 30, 2014. Dyax will host a webcast and conference call at 5:00 p.m. (ET) today to review financial results and provide updates regarding its key value drivers -including the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio (LFRP).
DYAX: 13.35 (-0.12)

Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 4:35PM CDT

EA: 41.40 (+0.20), BXP: 127.35 (+0.55), AMP: 129.99 (-0.29), MRCY: 13.53 (-0.10), BLDP: 2.55 (unch), ESRX: 77.63 (-0.21), AJG: 48.25 (+0.35), NANO: 14.19 (+0.06), CAP: 22.64 (-0.06), EXTR: 3.74 (-0.01), HTA: 12.48 (+0.08), AEC: 19.58 (+0.10), MCK: 204.51 (+1.38), BGFV: 13.30 (-0.08), FB: 74.15 (-0.57), ARI: 16.49 (-0.01), EXP: 85.76 (-1.75), MWA: 9.83 (-0.11), DYAX: 13.35 (-0.12), FARO: 55.60 (-0.90), NFX: 32.42 (-0.69), KONA: 23.02 (+0.01), AZPN: 37.72 (-0.07), GILD: 103.93 (-2.97), HIW: 42.17 (-0.11), PEI: 21.76 (+0.22), GFIG: 4.86 (+0.01), CHRW: 72.91 (+0.05), HURN: 69.39 (-0.86), DLR: 68.60 (+0.20), HLIT: 6.87 (-0.03), AMCC: 6.24 (-0.10), INVN: 14.27 (+0.01), BOOM: 17.07 (-0.21), CINF: 51.55 (+0.28), KIM: 24.85 (+0.25), OI: 25.58 (-0.30), GPRE: 33.16 (-0.45), EPR: 56.84 (+0.25), APC: 89.23 (-2.19), IPHI: 14.36 (-0.17), HTS: 19.08 (-0.02), MAR: 77.82 (+0.52), INAP: 7.98 (-0.02), CRAY: 34.09 (-0.36), FEIC: 82.62 (-0.47), FISV: 70.28 (+0.43), DNB: 124.97 (-0.04), AFG: 60.55 (+0.08), CEB: 74.97 (-0.49), KEYW: 10.91 (-0.07), PLT: 52.08 (-0.31), MAC: 68.93 (+0.33), CHMT: 23.42 (-0.07), AFL: 59.17 (-0.04), CBT: 46.70 (-0.67), EIX: 62.32 (-0.08), EQR: 69.92 (+0.61)

Shares of DYAX Up 41.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Oct 27, 9:38AM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 41.60% as of today's recent price of $10.74.
DYAX: 13.35 (-0.12)

Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon
PR Newswire - Mon Oct 27, 7:35AM CDT
Investor-Edge has initiated coverage on the following equities: Neurocrine Biosciences Inc. (NASDAQ: NBIX), Insmed Inc. (NASDAQ: INSM), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Dyax Corporation (NASDAQ: DYAX), and Oncothyreon Inc. (NASDAQ: ONTY). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 24, 2014, the NASDAQ Composite ended at 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced 0.76%, to finish the day at 16,805.41, and the S&P 500 closed at 1,964.58, up 0.71%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 754.42, up 1.38%, with the index also advancing 5.41% in the previous three months. Register for your complimentary reports on these five stocks at:
INSM: 14.58 (+0.37), BCRX: 10.74 (-0.04), NBIX: 19.20 (-0.08), ONTY: 1.73 (+0.01), DYAX: 13.35 (-0.12)

Dyax Has Returned 31.6% Since SmarTrend Recommendation (DYAX)
Comtex SmarTrend(R) - Mon Oct 20, 9:12AM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 31.58% as of today's recent price of $9.98.
DYAX: 13.35 (-0.12)

Dyax Corp. to Host Third Quarter 2014 Earnings Call and Webcast
Business Wire - Tue Oct 14, 7:00AM CDT
Dyax Corp. (NASDAQ

YAX) will host a webcast and conference call, including an open question and answer session, Tuesday, October 28, 2014. During the call, management will discuss the Company's financial results for the third quarter 2014 as well as progress regarding its key value drivers - the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio (LFRP).
DYAX: 13.35 (-0.12)

Dyax Up 25.6% Since SmarTrend Uptrend Call (DYAX)
Comtex SmarTrend(R) - Fri Oct 10, 5:12PM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 25.64% as of today's recent price of $9.53.
DYAX: 13.35 (-0.12)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

QuickFi Nabs Top Finovate Award for Fourth Time

An Unstoppable Force in Fintech Well, if QuickFi hasn't made a name for itself in fintech, then folks, I don't know what to tell you. This year, they’ve snagged yet another prestigious Finovate Award—this time for Best SMB/SME Banking Solution. That's not their first rodeo either; it’s the fourth time they’ve walked away winners. It's almost like they're...

Melissa Rivers Brings Her Wit Back to Emmys Carpet

They say you can never go home again, but don't tell that to Melissa Rivers. Rolling the dice on nostalgia and kicking off a new chapter, she's waltzing back to the Emmys red carpet for the first time in nearly 20 years. Alright, what's in it for investors? Not much—unless you're looking to invest in nostalgia. But there's something here about legacy, reinvention, and...

Fermi's Founder Pushes for Board Overhaul: What's Next?

Fermi's Roller Coaster: A Founder’s Stand Seems like Fermi Inc. is on a wild ride through the business landscape, and it's giving shareholders more whiplash than satisfaction these days. Toby Neugebauer, co-founder of Fermi and the loudest voice in the room, is feeling like his company is facing some serious turbulence and seems determined not to sit idly by as it hits...

Supply Maverick Simplifies Global Shipping Processes

Paving the Way for Seamless International Shipping Supply Maverick's got a new mantra, folks: simplicity. They're slicing through the mess of international shipping and bringing some much-needed clarity for customers in Canada, Australia, and New Zealand. It’s about time someone shook up the logistics playbook. The Nuts and Bolts of the New Shipping System Imagine being...

Lick the Plate Hits 2,000 Shows with Clown Band

They say good things come in bizarre packages, and that's exactly the case as David Boylan's Lick the Plate zany celebration marks 15 years on air with its 2,000th episode. If you think of radio as a predictable endeavor, well, you're not tuned into Lick the Plate. A Milepost Draped in Multicolored Fabrics When you're browsing through colorful avenues of radio fame, it's...

High-Grade Copper Spurs Optimism for PolarX in Alaska

Copper's New Pulse: PolarX Makes Waves in Alaska Ever hear about striking copper so rich it's practically shimmering? Well, PolarX Limited just might have hit that sweet spot up in the rugged expanses of Alaska. Let me tell you, when you're knee-deep in resources, like what they’re discovering at the Caribou Dome Project, it sure feels like you’ve struck modern-day...

Streamlined AI Video Analytics for Public Safety Unveiled

AI Without the Headache Alright folks, IREX is shaking things up, and not in the usual iterative, bit-by-bit tech progression way. StreamVLM™ has been rolled out as the world's first vision-language model (VLM) analytics engine tailored for the public safety sector—specifically, for cloud platforms. I’ve been around the block enough times to spot a significant shift...

DCM Services Teams with AKUVO to Boost Estate Recoveries

Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...

Jari Spirits Set to Shake Up U.S. Market After Big Wins

Korean Spirits Jari Eyes U.S. Market Entry Some stories just have that perfect 'right time, right place' vibe, and CJ Foods' recent splash with their Korean spirits brand jari is one of them. Buckle up, because this one's about a Korean distilling sensation gearing up to hit American shores with a bang. Accolades Pave the Path Jari, the premium Korean distilled spirits...

2026 Buy-Side Index Reveals State Market Variance

Toss out your one-size-fits-all real estate predictions; the Q2 2026 Buy-Side Index just unveiled some real whoppers about the housing market. What we're seeing isn't your typical year-over-year growth across the board. Nope, we're seeing splits as sharp as a knife between states. Some places are shooting up in price, while others seem to be stuck in mud. Price Surges and...